Director Michelle Yanez resigns; Michael Jerman appointed to Inhibitor Therapeutics Board

Inhibitor Therapeutics, Inc.

Michelle Yanez resigned from the Board effective May 24, 2023, to take a full-time CFO role elsewhere; no disagreement with the company.
Michael Jerman, CPA, appointed as independent director and Chairman of the Audit Committee, effective May 24, 2023.
Jerman brings experience as CFO of private equity-backed companies, former PwC director, and USAF captain; deemed a financial expert.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Jerman

Director

INTI · Inhibitor Therapeutics, Inc.

Effective: 2023-05-24
Filed: May 31, 2023, 7:59 PM ET

On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an independent member of its Board.

Departed

Michelle Yanez

Director

INTI · Inhibitor Therapeutics, Inc.

Effective: 2023-05-24
Successor: Michael Jerman
Filed: May 31, 2023, 7:59 PM ET

On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Jerman was appointed as Director at Inhibitor Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an independent member of its Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michelle Yanez resigned as Director at Inhibitor Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”).

View on SEC.gov

Inhibitor Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.